Selank
Overview
A synthetic analog of the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with an added Pro-Gly-Pro sequence for stability. Selank exhibits anxiolytic activity comparable to benzodiazepines without sedation, dependence, or withdrawal effects. It modulates the expression of BDNF, serotonin, dopamine, and norepinephrine, and influences IL-6 and GABA receptor expression.
Key Research Findings
Approved in Russia for generalized anxiety disorder and as a nootropic. Clinical trials showed anxiolytic effects comparable to medazepam without sedation. Demonstrated immunomodulatory properties through modulation of IL-6 and T-helper cell balance.
Intranasal
Investigational
Interested in Selank?
Find a verified provider experienced with Selank protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Selank ProviderRelated Peptides
Semax
FDA ApprovedA synthetic heptapeptide analog of the ACTH(4-7) fragment (Met-Glu-His-Phe-Pro-Gly-Pro) with nootropic and neuroprotective properties. Semax modulates BDNF and NGF expression, enhances monoaminergic neurotransmission, and provides neuroprotection through anti-oxidant and anti-inflammatory mechanisms. It crosses the blood-brain barrier via intranasal administration.
Cerebrolysin
InvestigationalA porcine brain-derived peptide preparation consisting of low-molecular-weight neuropeptides and free amino acids that mimic the action of endogenous neurotrophic factors. Cerebrolysin exhibits neurotrophic activity similar to BDNF, GDNF, and CNTF, promoting neuronal survival, synaptic plasticity, and neurogenesis. It modulates GSK-3beta, CDK5, and calcineurin-NFAT signaling cascades involved in neurodegeneration.
P21 (Peptide)
Research PhaseA small synthetic peptide derived from the active region of ciliary neurotrophic factor (CNTF) designed to promote neurogenesis and synaptic plasticity. P21 is a tetrapeptide that crosses the blood-brain barrier and enhances dentate gyrus neurogenesis by increasing BDNF expression. Unlike full-length CNTF, P21 does not activate the JAK-STAT pathway or produce the anorectic and immunogenic effects of the parent protein.
Dihexa
Research PhaseDihexa is a small synthetic hexapeptide derived from angiotensin IV, designed to bind and potentiate hepatocyte growth factor (HGF) signaling through the c-Met receptor. This action is hypothesized to promote synaptogenesis, dendritic spine formation, and neuronal survival in models of cognitive impairment. Dihexa exhibits high oral bioavailability and blood-brain barrier penetration due to its small size and lipophilic character.